Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.
Bottom Line: The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).Three subgroup patients with tumour vaccine at 1-year, 2-year and 3-year survival rates also gained significant benefits compared with their corresponding control group (p=0.0004, 0.03 and 0.19, respectively).A few severe adverse effects occurred in the tumour vaccine group, but fewer side effects were observed in the vaccine group compared with the control group (p<0.00001).
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.Show MeSH
Related in: MedlinePlus
Mentions: Treatment-related adverse effects (AEs) (any grades and grades â‰¥3) and efficacy for patients with advanced NSCLC were evaluated in the 11 collected studies. The patients in the vaccine group observed fewer obvious side effects compared with the corresponding control group, such as nausea and vomiting, thrombocytopaenia and injection site reaction (pâ‰¤0.05). Patients receiving tumour vaccine therapy experienced six other AEs, which occurred equally in the control group, including anaemia, leucopaenia, body pain, fatigue, fever, headache, anorexia, arthralgia and dyspnoea (p>0.05; figure 4). Furthermore, we separately considered the adverse effects of grades â‰¥3. The pooled analysis showed that the patients who received vaccine treatment experienced a few severe adverse effects (grades â‰¥3), including nausea and vomiting (p=0.57), body pain (p=0.19) and anorexia (p=0.27), which did not generate statistical difference compared with the corresponding control group (figure 5). Heterogeneity was observed; the random effects models were used for side effect and serious AE analysis.
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.